Clinical Trials

At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer. An important part of developing new treatments is conducting clinical trials. eFFECTOR is currently recruiting patients to be part of clinical trials to test potential new products.

Now Enrolling

A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy that are experiencing Insufficient Response to Checkpoint Inhibitor Alone

Disease:
Non-small cell lung cancer, bladder cancer, head and neck cancer, hepatocellular cancer and others.

Active, not recruiting.

More Info Clinical Trial

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Disease:
Solid tumors with activating mutation, amplification or fusion of HER2, ERBB3, FGFR1, FGFR2, EGFR or an activating mutation in KRAS, pancreatic adenocarcinoma.

Actively recruiting.

More Info Clinical Trial

Expanded Access Policy

eFFECTOR Therapeutics is driven by science, and we are committed to developing safe and effective therapies for patients. Our goal is to provide our novel treatments to patients as quickly as possible, but in a way that stands up to scientific rigor and achieves the best clinical outcomes.
Our clinical programs are designed to answer important scientific questions about the potential risks and benefits of our product candidates, and to provide data to support regulatory approval. Patients are required to meet specific eligibility criteria to enter our clinical trials, and not every patient will meet eligibility criteria. When a patient does not meet the eligibility criteria for a clinical trial, or if a clinical trial is not available, and the patient has exhausted available treatment options, companies may consider providing access to its investigational medicines outside of a clinical trial through a process called Expanded Access.

eFFECTOR has determined that Expanded Access cannot currently be offered for any of its product candidates and the company does not currently provide its product candidates outside of enrollment in clinical trials.

If you have questions regarding this policy or any of our ongoing clinical trials, please contact: clinicaltrials@eFFECTOR.com